Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992–2002)

Jane M. Turrel Veterinary Oncology Specialties, 225 Carmel Ave, Pacifica, CA 94044.

Search for other papers by Jane M. Turrel in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM, DACVR
,
John Farrelly Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by John Farrelly in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM, DACVR
,
Rodney L. Page Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Rodney L. Page in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM
, and
Margaret C. McEntee Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Margaret C. McEntee in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM, DACVR

Click on author name to view affiliation information

Abstract

Objective—To determine the efficacy of strontium 90 β irradiation in the management of cutaneous mast cell tumors (CMCTs) in cats.

Study Design—Retrospective case series.

Animals—35 client-owned cats with CMCTs.

Procedure—Medical records of cats with CMCTs in which tumors were radiated by use of a strontium 90 ophthalmic applicator from 1992 to 2002 were reviewed. Cats were included if CMCT was diagnosed, there were no other sites of MCT involvement at the time of treatment, and records contained adequate follow-up information to permit retrospective assessment of local tumor control.

Results—54 tumors in 35 cats were treated with a median dose of 135 Gy of strontium 90 β irradiation, resulting in local tumor control in 53 of 54 (98%) tumors with a median follow-up time of 783 days after treatment. Median survival time was 1,075 days. Adverse effects of treatment appeared to be infrequent and of mild severity.

Conclusions and Clinical Relevance—Results indicated that strontium 90 β irradiation resulted in long-term tumor control and should be considered an effective alternative to surgical resection in management of CMCTs in cats.

Abstract

Objective—To determine the efficacy of strontium 90 β irradiation in the management of cutaneous mast cell tumors (CMCTs) in cats.

Study Design—Retrospective case series.

Animals—35 client-owned cats with CMCTs.

Procedure—Medical records of cats with CMCTs in which tumors were radiated by use of a strontium 90 ophthalmic applicator from 1992 to 2002 were reviewed. Cats were included if CMCT was diagnosed, there were no other sites of MCT involvement at the time of treatment, and records contained adequate follow-up information to permit retrospective assessment of local tumor control.

Results—54 tumors in 35 cats were treated with a median dose of 135 Gy of strontium 90 β irradiation, resulting in local tumor control in 53 of 54 (98%) tumors with a median follow-up time of 783 days after treatment. Median survival time was 1,075 days. Adverse effects of treatment appeared to be infrequent and of mild severity.

Conclusions and Clinical Relevance—Results indicated that strontium 90 β irradiation resulted in long-term tumor control and should be considered an effective alternative to surgical resection in management of CMCTs in cats.

All Time Past Year Past 30 Days
Abstract Views 227 0 0
Full Text Views 926 745 129
PDF Downloads 409 212 13
Advertisement